Current blood cancer drug prices not justified, study finds

The costs associated with cancer drug prices have risen dramatically over the past 15 years, which is of concern to many top oncologists. In a new analysis, researchers concluded that the majority of existing treatments for hematologic, or blood, cancers are currently priced too high to be considered cost-effective in the United States. (Mehr in: Cancer News — ScienceDaily)